Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Luca Laurenti; Francesca R. Mauro; Stefano Molica; Agostino Cortelezzi; Angelo M. Carella; Francesco Zaja; Annalisa Chiarenza; Francesco Angrilli; Francesco Nobile; Roberto Marasca; Caterina Musolino; Maura Brugiatelli; Alfonso Piciocchi; Marco Vignetti; Paola Fazi; Giuseppe Gentile; Maria S. De Propris; Irene Della Starza; Marilisa Marinelli; Sabina Chiaretti; Ilaria Del Giudice; Mauro Nanni; Francesco Albano; Antonio Cuneo; Anna Guarini; Robin Foà

doi:10.1016/j.leukres.2013.11.009

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Luca Laurenti, Francesca R. Mauro, Stefano Molica, Agostino Cortelezzi, Angelo M. Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S. De Propris, Irene Della Starza, Marilisa Marinelli, Sabina ChiarettiIlaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà

Research output: Contribution to journal › Article

7 Citations (Scopus)

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Original language	English
Pages (from-to)	198-203
Number of pages	6
Journal	Leukemia Research
Volume	38
DOIs	https://doi.org/10.1016/j.leukres.2013.11.009
Publication status	Published - 2014

Keywords

Alemtuzumab
Biology
CLL
Chronic lymphocytic leukemia
Fludarabine
Young

Access to Document

10.1016/j.leukres.2013.11.009

Cite this

Laurenti, L., Mauro, F. R., Molica, S., Cortelezzi, A., Carella, A. M., Zaja, F., Chiarenza, A., Angrilli, F., Nobile, F., Marasca, R., Musolino, C., Brugiatelli, M., Piciocchi, A., Vignetti, M., Fazi, P., Gentile, G., De Propris, M. S., Starza, I. D., Marinelli, M., ... Foà, R. (2014). Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 38, 198-203. https://doi.org/10.1016/j.leukres.2013.11.009

@article{ad7735b1678940009e781877a6c91d53,

title = "Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile",

abstract = "In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab({\textregistered})) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.",

keywords = "Alemtuzumab, Biology, CLL, Chronic lymphocytic leukemia, Fludarabine, Young, Alemtuzumab, Biology, CLL, Chronic lymphocytic leukemia, Fludarabine, Young",

author = "Luca Laurenti and Mauro, {Francesca R.} and Stefano Molica and Agostino Cortelezzi and Carella, {Angelo M.} and Francesco Zaja and Annalisa Chiarenza and Francesco Angrilli and Francesco Nobile and Roberto Marasca and Caterina Musolino and Maura Brugiatelli and Alfonso Piciocchi and Marco Vignetti and Paola Fazi and Giuseppe Gentile and {De Propris}, {Maria S.} and Starza, {Irene Della} and Marilisa Marinelli and Sabina Chiaretti and {Del Giudice}, Ilaria and Mauro Nanni and Francesco Albano and Antonio Cuneo and Anna Guarini and Robin Fo{\`a}",

year = "2014",

doi = "10.1016/j.leukres.2013.11.009",

language = "English",

volume = "38",

pages = "198--203",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Oxford,United Kingdom: Elsevier Science Limited -Oxford : Pergamon, 1977-",

}

Laurenti, L, Mauro, FR, Molica, S, Cortelezzi, A, Carella, AM, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, MS, Starza, ID, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A & Foà, R 2014, 'Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile', Leukemia Research, vol. 38, pp. 198-203. https://doi.org/10.1016/j.leukres.2013.11.009

TY - JOUR

T1 - Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

AU - Laurenti, Luca

AU - Mauro, Francesca R.

AU - Molica, Stefano

AU - Cortelezzi, Agostino

AU - Carella, Angelo M.

AU - Zaja, Francesco

AU - Chiarenza, Annalisa

AU - Angrilli, Francesco

AU - Nobile, Francesco

AU - Marasca, Roberto

AU - Musolino, Caterina

AU - Brugiatelli, Maura

AU - Piciocchi, Alfonso

AU - Vignetti, Marco

AU - Fazi, Paola

AU - Gentile, Giuseppe

AU - De Propris, Maria S.

AU - Starza, Irene Della

AU - Marinelli, Marilisa

AU - Chiaretti, Sabina

AU - Del Giudice, Ilaria

AU - Nanni, Mauro

AU - Albano, Francesco

AU - Cuneo, Antonio

AU - Guarini, Anna

AU - Foà, Robin

PY - 2014

Y1 - 2014

N2 - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

AB - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

KW - Alemtuzumab

KW - Biology

KW - CLL

KW - Chronic lymphocytic leukemia

KW - Fludarabine

KW - Young

KW - Alemtuzumab

KW - Biology

KW - CLL

KW - Chronic lymphocytic leukemia

KW - Fludarabine

KW - Young

UR - http://hdl.handle.net/10807/51028

U2 - 10.1016/j.leukres.2013.11.009

DO - 10.1016/j.leukres.2013.11.009

M3 - Article

VL - 38

SP - 198

EP - 203

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this